SEARCH

SEARCH BY CITATION

References

  • 1
    Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A. and Caligiuri, M. A., Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002. 100: 19351947.
  • 2
    Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M. and Smyth, M. J., DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J. Immunol. 2010. 184: 902911.
  • 3
    Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L. and Spies, T., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999. 285: 727729.
  • 4
    Raulet, D. H., Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 2003. 3: 781790.
  • 5
    El-Sherbiny, Y. M., Meade, J. L., Holmes, T. D., McGonagle, D., Mackie, S. L., Morgan, A. W., Cook, G.et al.,The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007. 67: 84448449.
  • 6
    Marras, F., Bozzano, F. and De Maria, A., Involvement of activating NK-cell receptors and their modulation in pathogen immunity. J. Biomed. Biotechnol. 2011. 2011: 152430.
  • 7
    Smyth, M. J., Cretney, E., Kelly, J. M., Westwood, J. A., Street, S. E. A., Yagita, H., Takeda, K. et al., Activation of NK-cell cytotoxicity. Mol. Immunol. 2005. 42: 501510.
  • 8
    Berg, M., Lundqvist, A., McCoy, P., Jr., Samsel, L., Fan, Y., Tawab, A. and Childs, R., Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009. 11: 341355.
  • 9
    Hatoum, H. T., Lin, S. J., Smith, M. R., Guo, A. and Lipton, A., Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin. Breast Cancer 2011. 11: 177183.
  • 10
    Hebbeler, A. M., Cairo, C., Cummings, J. S. and Pauza, C. D., Individual Vgamma2-Jgamma1.2 +T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens. Cancer Immunol. Immunother. 2007. 56: 819829.
  • 11
    Dieli, F., Gebbia, N., Poccia, F., Caccamo, N., Montesano, C., Fulfaro, F., Arcara, C. et al., Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003. 102: 23102311.
  • 12
    Maniar, A., Zhang, X., Lin, W., Gastman, B. R., Pauza, C. D., Strome, S. E. and Chapoval, A. I., Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010. 116: 17261733.
  • 13
    Todaro, M., D'Asaro, M., Caccamo, N., Iovino, F., Francipane, M. G., Meraviglia, S., Orlando, V. et al., Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J. Immunol. 2009. 182: 72877296.
  • 14
    Nussbaumer, O., Gruenbacher, G., Gander, H. and Thurnher, M., DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by gammadelta T lymphocytes. Blood 2011. 118: 27432751.
  • 15
    Su, X., Zhang, L., Jin, L., Ye, J., Guan, Z. and Chen, R., Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells. J. Clin. Immunol. 2010. 30: 766774.
  • 16
    Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita, H. et al., Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 2001. 193: 661670.
  • 17
    Matsumura, T., Ato, M., Ikebe, T., Ohnishi, M., Watanabe, H. and Kobayashi, K., Interferon-gamma-producing immature myeloid cells confer protection against severe invasive group A Streptococcus infections. Nat. Commun. 2012. 3: 678.
  • 18
    Taieb, J., Chaput, N., Menard, C., Apetoh, L., Ullrich, E., Bonmort, M., Pequignot, M. et al., A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 2006. 12: 214219.
  • 19
    Tateishi, K., Ohta, M., Guleng, B., Kanai, F., Tanaka, Y., Asaoka, Y., Jazag, A. et al., TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors. Int. J. Cancer 2006. 118: 22372246.
  • 20
    Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F. et al., Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 2006. 12: 693698.
  • 21
    Chou, A. H., Tsai, H. F., Lin, L. L., Hsieh, S. L., Hsu, P. I. and Hsu, P. N., Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J. Immunol. 2001. 167: 13471352.
  • 22
    Silverman, S. L., Kriegman, A., Goncalves, J., Kianifard, F., Carlson, T. and Leary, E., Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int. 2011. 22: 23372345.
  • 23
    Scheller, E. L., Hankenson, K. D., Reuben, J. S. and Krebsbach, P. H., Zoledronic acid inhibits macrophage SOCS3 expression and enhances cytokine production. J. Cell Biochem. 2011. 112: 33643372.
  • 24
    Reuben, J. S., Dinh, L., Lee, J., Stateson, J., Kamara, H., Xiang, L. and Opperman, L. A., Bisphosphonates inhibit phosphorylation of signal transducer and activator of transcription 3 and expression of suppressor of cytokine signaling 3: implications for their effects on innate immune function and osteoclastogenesis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol Endod. 2011. 111: 196204.
  • 25
    Roelofs, A. J., Jauhiainen, M., Monkkonen, H., Rogers, M. J., Monkkonen, J. and Thompson, K., Peripheral blood monocytes are responsible for gammadelta T-cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br. J. Haematol. 2009. 144: 245250.
  • 26
    Laderach, D., Wesa, A.andGaly, A., 4–1BB-ligand is regulated on human dendritic cells and induces the production of IL-12. Cell Immunol. 2003. 226: 3744.
  • 27
    Lundqvist, A., Abrams, S. I., Schrump, D. S., Alvarez, G., Suffredini, D., Berg, M. and Childs, R., Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006. 66: 73177325.
  • 28
    Seol, D. W., p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem. Biophys. Res. Commun. 2011. 416: 222225.
  • 29
    Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., Gil, M. et al., Breast-cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 2011. 365: 13961405.
  • 30
    Dieli, F., Vermijlen, D., Fulfaro, F., Caccamo, N., Meraviglia, S., Cicero, G., Roberts, A. et al., Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007. 67: 74507457.
  • 31
    Sheikh, N. A. and Jones, L. A., CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol. Immunother. 2008. 57: 13811390.
  • 32
    D'Arcy, P., Brnjic, S., Olofsson, M. H., Fryknas, M., Lindsten, K., De Cesare, M., Perego, P. et al., Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 2011. 17: 16361640.